Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “RAI-Refractory Thyroid Cancer”

20 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 20 results

Testing effectiveness (Phase 2)UnknownNCT04554680
What this trial is testing

Clinical Trial in RAI-Refractory Thyroid Carcinoma Evaluating BRAF & MEK Blockade for Re-differentiation Therapy

Who this might be right for
Thyroid Cancer
National University Hospital, Singapore 5
Not applicableLooking for participantsNCT06443866
What this trial is testing

I-124 PET/CT Imaging and Dosimetry for RAI-Naïve or Refractory Thyroid Cancer

Who this might be right for
Thyroid CancerRAI-Refractory Thyroid Cancer
Miami Cancer Research Center, Inc. 50
Testing effectiveness (Phase 2)UnknownNCT02041260
What this trial is testing

A Phase II Trial of Cabozantinib for the Treatment of Radioiodine (RAI)-Refractory Differentiated Thyroid Carcinoma (DTC) in the First-line Setting

Who this might be right for
Differentiated Thyroid Cancer (DTC)Poorly Differentiated Thyroid Cancer
Thomas Jefferson University 43
Testing effectiveness (Phase 2)Study completedNCT03244956
What this trial is testing

Efficacy of MEK (Trametinib) and BRAFV600E (Dabrafenib) Inhibitors With Radioactive Iodine (RAI) for the Treatment of Refractory Metastatic Differentiated Thyroid Cancer

Who this might be right for
Metastatic Radioactive Iodine Refractory Thyroid Cancer Patients With RAS or BRAF Mutation
Gustave Roussy, Cancer Campus, Grand Paris 40
Large-scale testing (Phase 3)Study completedNCT01876784
What this trial is testing

Evaluation of Efficacy, Safety of Vandetanib in Patients With Differentiated Thyroid Cancer

Who this might be right for
Differentiated Thyroid Cancer
Genzyme, a Sanofi Company 238
Testing effectiveness (Phase 2)Ended earlyNCT00525135
What this trial is testing

Valproic Acid (Depakote ER) in Patients With Advanced Thyroid Cancer

Who this might be right for
Head and Neck Cancer
University of California, San Francisco 5
Early research (Phase 1)Study completedNCT02456701
What this trial is testing

Enhancing Radioiodine Incorporation Into BRAF Mutant Thyroid Cancers With the Combination of Vemurafenib and KTN3379

Who this might be right for
Thyroid Cancer
Celldex Therapeutics 7
Not applicableNot Yet RecruitingNCT07770074
What this trial is testing

A Real-World Study of Second-line Therapies Among Radioiodine-refractory Differentiated Thyroid Cancer (RAI-R DTC) Patients

Who this might be right for
Radioiodine-refractory Differentiated Thyroid Cancer
Novartis Pharmaceuticals 200
Not applicableStudy completedNCT02303444
What this trial is testing

An Observational Study in Differentiated Thyroid Cancer Which is Radioactive Iodine (RAI) Refractory to Assess the Use of Multikinase Inhibitors

Who this might be right for
Thyroid Neoplasms
Bayer 667
Testing effectiveness (Phase 2)Looking for participantsNCT05668962
What this trial is testing

Restor. I-131 Upt. + Selpercatinib in RET F-P RAI-R TC

Who this might be right for
Thyroid CancerThyroid CarcinomaMetastatic Thyroid Cancer+3 more
Massachusetts General Hospital 30
Large-scale testing (Phase 3)Study completedNCT00984282
What this trial is testing

Nexavar® Versus Placebo in Locally Advanced/Metastatic RAI-Refractory Differentiated Thyroid Cancer

Who this might be right for
Thyroid Neoplasms
Bayer 417
Large-scale testing (Phase 3)Looking for participantsNCT06475989
What this trial is testing

Study of Targeted Therapy vs. Chemotherapy in Patients With Thyroid Cancer

Who this might be right for
Refractory Differentiated Thyroid Gland Carcinoma
ECOG-ACRIN Cancer Research Group 264
Testing effectiveness (Phase 2)Study completedNCT00098813
What this trial is testing

Romidepsin in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer That Has Not Responded to Radioactive Iodine

Who this might be right for
Recurrent Thyroid CancerStage IV Follicular Thyroid CancerStage IV Papillary Thyroid Cancer
National Cancer Institute (NCI) 20
Very early researchStudy completedNCT02145143
What this trial is testing

Enhancing Radioiodine (RAI) Incorporation Into BRAF Mutant, RAI-Refractory Thyroid Cancers With the BRAF Inhibitor Vemurafenib: A Pilot Study

Who this might be right for
Thyroid Carcinoma
Memorial Sloan Kettering Cancer Center 12
Testing effectiveness (Phase 2)Looking for participantsNCT03099356
What this trial is testing

Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer

Who this might be right for
Metastatic Thyroid Cancer
University of Michigan Rogel Cancer Center 22
Testing effectiveness (Phase 2)Active Not RecruitingNCT02152995
What this trial is testing

Trametinib in Increasing Tumoral Iodine Incorporation in Patients With Recurrent or Metastatic Thyroid Cancer

Who this might be right for
Metastatic Thyroid Gland CarcinomaPoorly Differentiated Thyroid Gland CarcinomaRecurrent Thyroid Gland Carcinoma+9 more
National Cancer Institute (NCI) 34
Not applicableStudy completedNCT00970359
What this trial is testing

Reacquisition of Radioactive Iodine (RAI) Uptake of RAI-Refractory Metastatic Thyroid Cancers by Pretreatment With the Selective MEK Inhibitor AZD6244

Who this might be right for
Thyroid Cancer
Memorial Sloan Kettering Cancer Center 24
Testing effectiveness (Phase 2)Looking for participantsNCT06007924
What this trial is testing

Avutometinib and Defactinib in People With Thyroid Cancer

Who this might be right for
Thyroid Cancer
Memorial Sloan Kettering Cancer Center 30
Not applicableLooking for participantsNCT05733013
What this trial is testing

Collect Information About the Use of Redifferentiating Medications as a Standard Treatment for Thyroid Cancer

Who this might be right for
Thyroid CancerThyroidRefractory Thyroid Cancer
Memorial Sloan Kettering Cancer Center 100
Testing effectiveness (Phase 2)Study completedNCT03246958
What this trial is testing

Nivolumab Plus Ipilimumab in Thyroid Cancer

Who this might be right for
Thyroid Cancer
Dana-Farber Cancer Institute 53
Next Page